Efficacy and safety of pyrotinib in advanced lung adenocarcinoma with HER2 mutations: a multicenter, single-arm, phase II trial.

MLA

Song, Zhengbo, et al. “Efficacy and Safety of Pyrotinib in Advanced Lung Adenocarcinoma with HER2 Mutations: A Multicenter, Single-Arm, Phase II Trial.” BMC Medicine, vol. 20, no. 1, Feb. 2022, p. 42. EBSCOhost, https://doi.org/10.1186/s12916-022-02245-z.

APA

Song, Z., Li, Y., Chen, S., Ying, S., Xu, S., Huang, J., Wu, D., Lv, D., Bei, T., Liu, S., Huang, X., Xie, C., Wu, X., Fu, J., Hua, F., Wang, W., Xu, C., Gao, C., Cai, S., … Zhang, Y. (2022). Efficacy and safety of pyrotinib in advanced lung adenocarcinoma with HER2 mutations: a multicenter, single-arm, phase II trial. BMC Medicine, 20(1), 42. https://doi.org/10.1186/s12916-022-02245-z

Chicago

Song, Zhengbo, Yuping Li, Shiqing Chen, Shenpeng Ying, Shuguang Xu, Jianjin Huang, Dan Wu, et al. 2022. “Efficacy and Safety of Pyrotinib in Advanced Lung Adenocarcinoma with HER2 Mutations: A Multicenter, Single-Arm, Phase II Trial.” BMC Medicine 20 (1): 42. doi:10.1186/s12916-022-02245-z.